A Randomised, Double-blind, Sequential, Ascending Single-dose Study to Evaluate Safety, Tolerability, Biological Activity, and Systemic Exposure of COVA322, a Bispecific TNF-α / IL-17A Antibody Fusion Protein, in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis

Trial Profile

A Randomised, Double-blind, Sequential, Ascending Single-dose Study to Evaluate Safety, Tolerability, Biological Activity, and Systemic Exposure of COVA322, a Bispecific TNF-α / IL-17A Antibody Fusion Protein, in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs COVA 322 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Covagen
  • Most Recent Events

    • 16 Feb 2016 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 12 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
    • 05 May 2014 Top-line data are expected in the first quarter of 2015, according to a Covagen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top